JenaValve Technology, Inc.

50 articles about JenaValve Technology, Inc.

• egnite, Inc. and JenaValve Announce Novel Research on Outcomes with Untreated Aortic Regurgitation at the 2024 American College of Cardiology Conference

  4/6/2024

  egnite, Inc., a leading digital health company for cardiovascular care, and JenaValve Technology, Inc., a developer and manufacturer of differentiated transcatheter aortic valve replacement systems, unveil a novel study presented at the American College of Cardiology’s Annual Scientific Session & Expo.

• JenaValve Announces Publication of ALIGN-AR Pivotal Trial Results in The Lancet

  3/28/2024

  JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced the publication of results from the ALIGN-AR Pivotal Trial in The Lancet.

• JenaValve’s Trilogy THV System Highlighted at CRT 2024

  3/19/2024

  JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve System, announced highlights from the Cardiovascular Research Technologies Conference 2024.

• JenaValve Featured at the PCR London Valves 2023

  12/6/2023

  JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve System, announced highlights from PCR London Valves 2023, a leading, annual global valve conference.

• JenaValve Appoints Shlomi Nachman to Board of Directors

  9/14/2023

  JenaValve Technology, Inc. announced that it has appointed Shlomi Nachman, experienced cardiovascular industry executive, to its Board of Directors.

• egnite, Inc. and JenaValve Announce Strategic Partnership to Uncover Trends in Care for Patients with Aortic Regurgitation

  6/9/2023

  egnite, Inc. and JenaValve Technology, Inc. are pleased to announce a strategic partnership aimed to shed light on the care paradigm and associated outcomes of patients with aortic regurgitation.

• JenaValve Announces First Trilogy Heart Valve Systems Implanted in Asia

  5/18/2023

  JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement systems, announced the completion of the first two Trilogy Heart Valve System implantations in Asia.

• JenaValve Appoints Dan Dearen to Board of Directors

  1/5/2023

  JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement systems, announced that it has appointed Dan Dearen, medical device industry executive, to its Board of Directors.

• JenaValve Appoints Duane Pinto, MD, MPH, as Chief Medical Officer

  10/24/2022

  JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement systems, announced that Duane Pinto, MD, MPH, has been appointed as Chief Medical Officer.

• JenaValve Completes Enrollment in the ALIGN-AR IDE Clinical Trial

  9/14/2022

  JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement systems, announced the successful completion of patient enrollment in the ALIGN-AR Pivotal trial.

• 

  Money on the Move: Mesoblast, Iantrek, Jenavalve and More

  8/31/2022

  Mesoblast fell short of analyst forecasts this week, and money is pouring into glaucoma, medical devices for heart disease and chronic endocrine conditions.

• JenaValve Raises $100 Million to Advance Trilogy TAVR Solution

  8/31/2022

  JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement systems, announced that it has completed the initial closing of a $100 million Series C financing.

• JenaValve Announces Results from First Commercial Trilogy Heart Valve System Implants in Europe

  6/28/2022

  JenaValve Technology, Inc. (“JenaValve” or the “Company”), developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, announced positive results from the first Trilogy Heart Valve System commercial implants for high-surgical risk patients with severe, symptomatic aortic stenosis (AS) or aortic regurgitation (AR) in Europe, initially presented at EuroPCR 2022 on May 18.

• JenaValve Appoints Kari Moore as Chief Financial Officer

  5/17/2022

  JenaValve Technology, Inc. announced the appointment of Kari Moore as the Company’s CFO effective May 10th, 2022.

• JenaValve Announces Strategic Investment and Licensing Agreement with Peijia Medical Limited

  1/18/2022

  JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement systems, announced a strategic investment and exclusive technology licensing agreement with Peijia Medical Limited in China.

• JenaValve Announces First European Commercial Implants with the Trilogy™ Heart Valve System

  10/18/2021

  JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced the first commercial implants with the Trilogy Heart Valve System in Europe.

• JenaValve Receives IDE Approval to Initiate The ALIGN-AR Pivotal PMA Trial

  8/16/2021

  JenaValve Technology, Inc. today announced FDA approval for the company to initiate its Investigational Device Exemption (IDE) PMA clinical trial for the Trilogy™ Heart Valve System for severe symptomatic, high-surgical risk aortic regurgitation.

• JenaValve Technology Receives CE Mark for its Trilogy™ TAVI System for the Treatment of Aortic Regurgitation and Aortic Stenosis

  5/25/2021

  JenaValve Technology, Inc., developer, and manufacturer of differentiated transcatheter aortic valve implantation systems for the treatment of aortic valve disease, announced that it has received CE Mark for its TrilogyTM Heart Valve System for the treatment of both aortic regurgitation, also known as aortic insufficiency, and aortic stenosis.

• JenaValve Technology Appoints Peter L. Spadaro Chief Commercial Officer

  9/28/2020

  JenaValve Technology, Inc., developer and manufacturer of differentiated pericardial transcatheter aortic valve replacement (TAVR) systems for the treatment of aortic valve disease, announces the appointment of Peter L. Spadaro, Jr. to the newly created position of Chief Commercial Officer. Mr. Spadaro is a highly accomplished cardiovascular sales and marketing executive who has held senior positions at global industry l

• JenaValve Technology Closes $50 Million Financing

  2/5/2020

  JenaValve Technology, Inc., developer and manufacturer of the JenaValve Pericardial Transcatheter Aortic Valve Replacement System for the treatment of aortic valve disease, announces that it has raised $50 million in an equity financing led by Bain Capital Life Sciences.